Just a few days on a night shift schedule throws off protein rhythms related to blood glucose regulation, energy metabolism and inflammation, processes that can influence the development of chronic metabolic conditions. The finding, from a study led by scientists at Washington State University and the Pacific Northwest National Laboratory, provides new clues as to why night shift workers are more prone to diabetes, obesity and other metabolic disorders.

Researchers are studying an experimental Monoclonal Antibody drug in mice called mAB43, which targets insulin-making beta cells and shields them from attacks by immune system cells in type1 diabetes.

Millions worldwide live with type 1 diabetes, and for most the diagnosis came as a shock, following mysterious symptoms such as thirst and weight loss. But diabetes specialists have long known that certain blood tests can foretell the disease years earlier. That has left the field wrestling with a difficult question: Should healthy children get these blood tests, and would knowing about incipient diabetes help them? Early studies suggest antibody testing can prevent complications and delay disease, but some worry about psychological toll.

In late February, the Food and Drug Administration (FDA) warned diabetes patients not to use smartwatches or smart rings to measure their blood glucose levels. Following the FDA’s alert, obesity medicine expert Eleanor Yusupov, D.O., assistant professor at the College of Osteopathic Medicine, shares valuable insight for these patients.

Fifteen-year-old Mia Campos is living with Type 1 diabetes and can now enjoy everyday activities without any limitations thanks to her new "bionic pancreas." Campos's new “bionic pancreas” is a wearable, electronic device that replaces the role of her pancreas and adapts to the needs of her endocrine system over time. The iLet Insulin system was developed by Massachusetts-based Beta Bionics and is one of many new advances in diabetes management technology which are improving ways to automate insulin delivery.

“Precision medicine” involves customizing interventions to the unique genetic and molecular makeup of individual patients rather than relying on symptoms or broad categories. This approach, long associated with cancer treatment, is becoming increasingly critical for diabetes prevention and care. Precise diagnosis and disease characterization affect not only treatment choices but life planning, other health considerations, and even family members’ well-being. It means providing the right diagnosis, best care and insights into outcomes for all people with diabetes.

A recent study led by Indiana University School of Medicine in collaboration with the University of Chicago Medicine presents exciting future possibilities for the management of type 1 diabetes and the potential reduction of insulin dependency. The researchers’ findings, published in Cell Reports Medicine, suggest repurposing of the drug α-difluoromethylornithine (DFMO) may open doors to innovative therapies in the future.

The implantable device contains encapsulated cells that produce insulin, plus a tiny oxygen-producing factory that keeps the cells healthy. It could be enable injection-free control of diabetes.

For the well over 700 million people around the globe living with type 1 diabetes, getting a host immune system to tolerate the presence of implanted insulin-secreting cells could be life-changing. Rice University bioengineer Omid Veiseh and collaborators identified new biomaterial formulations that could help turn the page on type 1 diabetes treatment, opening the door to a more sustainable, long-term, self-regulating way to handle the disease. To do so, they developed a new screening technique that involves tagging each biomaterial formulation in a library of hundreds with a unique “barcode” before implanting them in live subjects.